Protokoly_diagnostiki_i_lechenia_zabolevany
.pdf•% — 3 &$ &
•" — 3 &$ &
.
2.? , V .
3.+ " 7_@! , % " ,$"$# $.
4.B " " + .
' % % & " Helicobacter Pylori.
' Helicobacter Pylori:
@ Helicobacter Pylori & &$ % 12- , % &$ %
(?). |
|
|
' " & |
$ Helicobacter Pylori |
|
& " 3 |
, " |
|
3 . |
|
|
" " + '! Helicobacter Pylori |
. |
|
+ " & % " &$ % 12- .
1.@ & " – & !-13, $ & # % " "Helicobacter pylori (?, 1b, NICE 2004). B & ,3 3 ( % & " 4- &" " ).(A, 1b)
2.' Helicobacter Pylori (HpSA) . + ,&$ & " .Helicobacter Pylori, 3 3 . (A.. 1 )
3.! " ( JgG Helicobacter Pylori). G & " & &$ " &$, $ & "Helicobacter Pylori . , & 2$ &$, & " % &Helicobacter Pylori. , "Helicobacter Pylori.(?, 1b)
4.B " & &
: " , |
, |
|
|
. @ |
|
" 3 "$ $ " & & . |
|||||
5. |
< |
. L & & |
" , |
||
$ & " % . , |
$ |
||||
" . |
|
|
|
||
6.; " , " 100 . " % & , . @ " & & 3 . (?, 1b)
7.& – & & Helicobacter Pylori, & #$ " & "
. B & & & " " & 2 " " 3 (B, 11a), 4.
' 3 - + $ $#
% .
" & :
1.# .
2." % .
3.? $ &.
4.# " .
5. 7_@! & ( ).
6." .
7./ " .
8.; + .
" & & :
2.H)B " , % " % " % .
3..
4..
5.?J;, ?!;.
6.$ .
8.% ( )
+
+>6>@B ?6>+; )+ > J>L>+B>
• @ 81 (1 , 15) $" $, $# $# "( , , "[ )., 5~ .
6>@B ?6>+; )+ > J>L>+B>
A & 8 |
% , |
. pylori |
3 |
'4. ; |
3 |
: |
|
|
•' % & " %$ +. pylori,, 80% " .
•+ % & % " 3 ( " 5% " ).
•! % & 3 % & " 7~14
.
; — 33 ?. 3 $85-90% " 15% " .
! " :
; .
B ( * 20 , ?* 20 ) - - * + ?* 500 + ?* 1000
* 500 |
; |
J! |
$ |
2 & |
" 7 |
. ! " |
||||
|
|
" & , |
" |
|
|
|||||
', % & %$ " |
& |
|
||||||||
" |
|
. 500 |
2 |
|
& |
|
||||
3 |
[ J! 250 2 &'. , " 3 & - |
|||||||||
- ? ** |
? . |
|
|
|
|
|||||
$ " 3 |
|
|||||||||
. B |
2 & + |
|||||||||
' 120 4 & + ?** 500 3 & + ?** 100-200 4 &.
1.> & " $ 3 , & [ .
2.> & 3 , 3 " , " " & " ( , ).
3.> & , " 3 ,& " & & +. pylori & .
4. & " " " $& , $.
5. 3 " .
" 3 |
% & " |
|
#[ " 5 & " 7 |
% " |
|
& |
( |
, |
+2- ). O &, H. pylori
' " , H . pylori, &$ " "$ " . % " .
• B : ?* 20 2 &, ?* 20 1-2 &,
•< +- : ?*20 2 &, '* 150 2&.
•— '*, .*
7 & " % $ 3 " " 8 , & — " 4 .
?. |
+ ( " % ) |
%$# |
||
|
. : 1. + 3 & |
|||
3 ,2. % O<, 3. + " $# , |
||||
$# |
+ '!, 4. |
! $# O< 3- $ -3 .,5. |
||
< & 60 % $# " O<. |
|
|||
<. ; |
$, |
$# , |
||
O< |
|
" - 3 , |
||
- |
- " 3 . > $, 7_@!, |
|||
|
- 3 . |
|||
" & :
1.*? 1000 ,
2.* 500 ,
3.*; 100-200 ,
4.*6 500 ,
3.* & $, &
4.*_ 40 ,
5.* 20 ,
" & & :
1. *' 120 ,
2. *@ 10 , ,- ! : " , ,
< & % $ $ .
/ |
, & |
: |
1. |
Prodigy guidance – Dyspepsia – proven DU, GU, or NSAID-associated ulcer. NICE 2004 |
|
Management of Helicobacter pylori Infection. MOH Clinical Practice Guidelines 9/2004 |
||
2. |
B.+.@ , M.J.K " . |
" $ " |
|
" . 6.2004. |
|
3.New Zealand guidelines group/ Management of dyspepsia and heartburn, June 2004.)
4.Management of Helicobacter pylory infection. Ministry of health clinical practice guidelines 9/2004/
5.Guidelines for clinical care. University of Michigan health system. May 2005.
6.Practice guidelines. Guidelines for the Management of Helicobacter pylori Infection/ THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 93, No. 12, 1998.
7.National Committee for Clinical Laboratory Standards/ Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow AerobicallyFift Edition/ Approved Standard NCCLS Document M7-F5,Vol.20, N!!LS, Wayne,PA,January 2000.
8.'.;. B . " $ ." . 6 ., 2005 .
9.& .O. " $ , 6 ,2001 .
10.?.'. + " # H" - " , ? ,2003 .
* – , # (% % )
!
"
( " )
# 2006 .
# 8 , $ . ' $ 8 8
: 09-101
"$ &: ":
& !: " # , % .
' & & ( ): 9
(: L02 ? % ,
) : # – " , $# " " # " ( & ). ? % % " : , . Staphylococcus aureus.
* – -" %$#
. ' & |
|
&$ |
% |
%$#$ |
&$ &. + " $ |
|
" |
% , |
$# |
$ ( "& , ) $ ( |
& , , " |
|||
&, ). ' " # Staphylococcus aureus, % Staphylococcus pyogenes albus. * – % % .
– -" & & % % % " . " # , % " " , , , % " . ' – Staphylococcus aureus, % .
* : # , , % # ,
# ( , % ), % . |
|
|||||
" : |
|
|
|
|
||
" |
|
: |
% |
, |
, |
|
$# , , . |
|
|
||||
5 : |
|
|||||
# , # " , , $. |
|
|||||
|
: |
– & |
||||
$# |
|
% , |
& " |
& |
||
" " ( ) . " |
|
, |
||||
3-7 & %$ . - " & & & , " . + % $ & , % $# , # , & . % &, % , " . 7 " & , & (" "),- . ' . &$, & % , " $ " . ; 40 !, " " & ( , , & &, , & ).
" & :
" & :
+ :
. % - " % % & . & & ,% & %$# . "# & % & % " .
> " 3 ,. $"" " $ # % " " . ", &$ ' .
@ $ & " " . 6 % " & , "& . H ,$ $ " . & $$ , " , , % % .$ . 2-3 $ % , " " , . ' " % "& % & "
|
|
, " % |
& |
|||
" 3 . |
|
|
|
|
|
|
|
|
, |
$# |
& |
|
|
$# , "$# # : 5% -2,0 / 810-15, 1 . 3 &, 10 .
? " " & :
_ – 0,25 4 / ( ); / – 0,375-0,625 3 / ;0,5-1,0 4 / ;– 0,5 2 / ; 3 0,5 4 / ;1-2 4-6 / / , / ;1-2 3 / / , / ;
0,5-1 3 / &;1, 0 1 / / .
B & 400 \ – 7 ( ).
6 - 2% & , 2% &.
H" " , &$ " $# : & 30% - 10,0 / % 810-15.
" " ## , , " " 1% 1,0 / 810-15 ( ", $, $# "
). |
|
||
+ "$ |
& & |
– 6 . |
|
# 10 . |
|
||
@ & |
/+! $ $# – |
|
|
|
20 . 3 & " . |
|
|
H" , " |
# " $ , |
||
% "$ – 500 3
&, 10 ; 250 3 &-10 . ! &$ |
% |
% " % , " % " # , |
|
" # " $# " 14 &, 10 .
! &$ " " - 400 / 1&, 800 . + % "$ , " –, ( , , & ), & , " % .
" & :
1.*? V 5%, 10% 2 , 5
2._ 500
3.*? + 625 ; V 600
4. */ 250 , 500 , ; 125 , 250 /5
5.*/ 250 , 500 ; V
|
750 |
6. |
*7 250 , 500 ; & 250 /5 |
7. |
*/ V 1000 |
8. |
*/ V 250 , 500 , 1 000 |
|
|
9.*B & 150 – 10 \
10.*+ & V 30% 5 , 10
11.*+ 50 ; 1% 1
12.*? & 250
13.+ 30 , 50
14.*6 10% &
15.*6 250 ; 0,5 100
16.* , % 4 500 >@
17.*@ 200 , 400
18.*6 1% 10
19.* 1:10 000
20.* & 3% 25 , 40
" & & :
,- ! : %
/ , & :
1.MedlinePlus. Furuncle and Carbunculosis;
2.) 6.+. % .
* – , # % % .
7 & & 8
: 12-120
"$ &: " :
& ! : & &3 , &
' & & ( ): 12
(: N41.1 G "
) : < - & %
. |
|
|
|
|
|
|
||
$ (+ & B ) & , !K?): |
|
|
||||||
- G " & |
|
|
|
|
|
|||
- G " & |
( " ) |
|
||||||
|
? - |
" |
|
|
|
|||
|
< - |
" |
& % |
|
||||
- < & % |
|
|
|
|||||
- & , . |
|
|
|
|
|
|||
* |
: |
|
$# |
|
, |
& |
, |
|
. |
|
|
|
|
|
|||
" : |
|
|
|
|
|
|||
" |
: < % , |
, |
% ( , |
|||||
& 3 & " ). |
|
|||||||
5 : |
|
|||||||
?6, , $, |
& % , |
" |
||||||
% |
& % , 2- |
, " " |
||||||
% , !? , / , B_?, B_, B_, , |
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
: |
|
|
|
|
|
1.H" # " , " %% % .
2. |
) " |
, " . |
|
3. |
L % " |
. |
|
4. |
L % , |
. |
|
5. |
< & " |
" |
|
6., 3 , 3 .
7.! % , " " 3 & & " .
8.J # " .
9.< & & % .
10. ' % & & % & .
11.< & " , " .
12.H)B: " .
" & :
1.# (6 )
2.# "
3." %
4.? " &
5.H)B "
" & & :
1. B_? G
2.B_? IgA
3.B_? IgM
4.B_? IgG
5.B_? IgM
6.B_?
7.B_?
8.B "
9.B_?
+ :
1. J 3 " ( " &
) ( |
400 2 &, |
250-500 2 &), 2,3 |
, + |
, ( , , , ),.
2.@ " && 400 \ " 7
3. |
œ- ( , 1-2 2,5 1 & 2,5 1- |
|
|
2 ) " & |
) (1,2) |
4. |
( , " |
) |
5.6 % & % , " , "( )
5. B ( , )
G " & . 7 & : œ-,5œ-, & ( & ), & , (5,6,7)
" / "& " " .
" & :
1. |
* V 40 / , 80 /2 |
2. |
*/ 250 , 500 ; V |
|
750 |
3.B & 150 – 10 \
4.+ 200
5." &
6.*6 , 250
7.*? 250 ; 250 , 500 ; V 500 , 1000 ; 125/5
" & & :
1. *? 200 ; 205
2.7 % 3 1
3.*J 250 , 500
,- ! :
% " , " " , &, B_?.
/ , & :
1.Chronic prostatitis. Thomas Jang and Anthony Schaeffer. Search date July 2004. BMJ;
2.Barbalias GA, Nikiforidis G, Liatsikos EN. Alpha-blockers for the treatment of chronic prostatitis in combination with antibiotics. J Urol 1998; 159: 883-887;
3.Prodigy Guidance - Prostatitis